MeiraGTx (MGTX) Competitors $6.55 +0.06 (+0.92%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGTX vs. KYMR, BLTE, BHC, JANX, AAPG, ARWR, HRMY, GLPG, CNTA, and ARQTShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Kymera Therapeutics (KYMR), Belite Bio (BLTE), Bausch Health Companies (BHC), Janux Therapeutics (JANX), Ascentage Pharma Group International (AAPG), Arrowhead Pharmaceuticals (ARWR), Harmony Biosciences (HRMY), Galapagos (GLPG), Centessa Pharmaceuticals (CNTA), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. MeiraGTx vs. Kymera Therapeutics Belite Bio Bausch Health Companies Janux Therapeutics Ascentage Pharma Group International Arrowhead Pharmaceuticals Harmony Biosciences Galapagos Centessa Pharmaceuticals Arcutis Biotherapeutics MeiraGTx (NASDAQ:MGTX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment. Do analysts rate MGTX or KYMR? MeiraGTx currently has a consensus price target of $24.50, indicating a potential upside of 275.77%. Kymera Therapeutics has a consensus price target of $56.36, indicating a potential upside of 71.93%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Kymera Therapeutics 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.87 Which has more volatility & risk, MGTX or KYMR? MeiraGTx has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Is MGTX or KYMR more profitable? Kymera Therapeutics has a net margin of -191.26% compared to MeiraGTx's net margin of -633.05%. Kymera Therapeutics' return on equity of -24.96% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets MeiraGTx-633.05% -146.38% -53.05% Kymera Therapeutics -191.26%-24.96%-20.27% Does the MarketBeat Community believe in MGTX or KYMR? MeiraGTx received 136 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 71.75% of users gave MeiraGTx an outperform vote while only 54.29% of users gave Kymera Therapeutics an outperform vote. CompanyUnderperformOutperformMeiraGTxOutperform Votes19371.75% Underperform Votes7628.25% Kymera TherapeuticsOutperform Votes5754.29% Underperform Votes4845.71% Which has higher earnings & valuation, MGTX or KYMR? MeiraGTx has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeiraGTx$33.28M15.45-$84.03M-$2.13-3.06Kymera Therapeutics$47.07M45.23-$146.96M-$2.97-11.04 Does the media favor MGTX or KYMR? In the previous week, Kymera Therapeutics had 4 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Kymera Therapeutics and 3 mentions for MeiraGTx. Kymera Therapeutics' average media sentiment score of 0.86 beat MeiraGTx's score of 0.85 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in MGTX or KYMR? 67.5% of MeiraGTx shares are held by institutional investors. 8.4% of MeiraGTx shares are held by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryKymera Therapeutics beats MeiraGTx on 11 of the 19 factors compared between the two stocks. Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$514.14M$2.92B$5.40B$7.67BDividend YieldN/A1.91%5.44%4.33%P/E Ratio-5.3930.7822.2118.28Price / Sales15.45469.70392.73105.58Price / CashN/A168.6838.2034.62Price / Book3.003.756.774.22Net Income-$84.03M-$72.06M$3.21B$247.51M7 Day Performance20.52%9.49%4.85%5.53%1 Month Performance-15.21%-8.61%-6.31%-4.21%1 Year Performance34.16%-20.57%16.24%4.44% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.668 of 5 stars$6.55+0.9%$24.50+274.0%+31.6%$516.50M$33.28M-5.41300Insider TradeNews CoverageKYMRKymera Therapeutics1.3565 of 5 stars$27.16+4.6%$56.36+107.5%-14.0%$1.76B$47.07M-11.61170Upcoming EarningsNews CoveragePositive NewsBLTEBelite Bio2.628 of 5 stars$54.69-3.0%$96.67+76.8%+58.9%$1.74BN/A-49.2710BHCBausch Health Companies4.1117 of 5 stars$4.72-7.5%$7.17+51.8%-39.3%$1.74B$9.63B-39.3319,900Upcoming EarningsAnalyst DowngradeNews CoverageGap UpJANXJanux Therapeutics2.663 of 5 stars$29.30-1.3%$95.25+225.1%-36.5%$1.73B$10.59M-25.0430Insider TradePositive NewsAAPGAscentage Pharma Group InternationalN/A$19.12+2.1%N/AN/A$1.66B$980.65M0.00600News CoverageGap UpARWRArrowhead Pharmaceuticals3.486 of 5 stars$12.08+7.5%$41.44+243.1%-45.3%$1.66B$2.50M-2.34400Options VolumeNews CoveragePositive NewsHRMYHarmony Biosciences4.6265 of 5 stars$28.50+0.1%$53.33+87.1%+0.2%$1.63B$714.73M13.51200Upcoming EarningsShort Interest ↓Positive NewsGLPGGalapagos0.6412 of 5 stars$24.64-0.1%$25.33+2.8%-13.4%$1.62B$275.65M0.001,310Earnings ReportNews CoverageCNTACentessa Pharmaceuticals3.034 of 5 stars$12.15-1.2%$27.71+128.1%+38.6%$1.62B$6.85M-7.94200Insider TradeNews CoveragePositive NewsARQTArcutis Biotherapeutics2.9634 of 5 stars$13.53+4.0%$18.80+39.0%+65.5%$1.61B$196.54M-7.56150Positive News Related Companies and Tools Related Companies KYMR Competitors BLTE Competitors BHC Competitors JANX Competitors AAPG Competitors ARWR Competitors HRMY Competitors GLPG Competitors CNTA Competitors ARQT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGTX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGTX Stock Free MGTX Stock Alerts